Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.732
Abstract: Revefenacin is a novel once‐daily, lung‐selective, long‐acting muscarinic antagonist developed as a nebulized inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease. In a randomized, 4‐way crossover study, healthy subjects received a single… read more here.
Keywords: muscarinic antagonist; long acting; prolong interval; healthy subjects ... See more keywords
Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2017.1276167
Abstract: ABSTRACT Introduction: Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para-sympathetic bronchoconstricting effects within the airways. For years, tiotropium, has been the cornerstone LAMA for chronic obstructive pulmonary disease (COPD) management. Recently,… read more here.
Keywords: chronic obstructive; long acting; obstructive pulmonary; developing drugs ... See more keywords
Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
Sign Up to like & getrecommendations! Published in 2018 at "BioMed Research International"
DOI: 10.1155/2018/7473690
Abstract: Severe asthma is associated with substantial morbidity and mortality. Therapies must be maximized to gain control of a patient's severe asthma; however, avoiding overtreatment is also important. The mainstays of asthma maintenance treatment are inhaled… read more here.
Keywords: antagonist tiotropium; muscarinic antagonist; long acting; tiotropium ... See more keywords
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Experimental Pharmacology"
DOI: 10.2147/jep.s259330
Abstract: Introduction Bronchodilators are the cornerstone of chronic obstructive pulmonary disease (COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination treatment play a pivotal role. Several LAMAs are already available on the market… read more here.
Keywords: chronic obstructive; acting muscarinic; muscarinic antagonists; long acting ... See more keywords